MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Abeona Therapeutics Inc

Затворен

4.67 4.71

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.41

Максимум

4.9

Ключови измерители

By Trading Economics

Служители

136

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+298.93% upside

Пазарни показатели

By TradingEconomics

Пазарна капитализация

4.4M

218M

Предишно отваряне

-0.04

Предишно затваряне

4.67

Abeona Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

22.04.2024 г., 23:00 ч. UTC

Значими двигатели на пазара

Abeona Therapeutics Shares Down 53% After FDA Complete Response Letter

Сравнение с други в отрасъла

Ценова промяна

Abeona Therapeutics Inc Прогноза

Ценова цел

By TipRanks

298.93% нагоре

12-месечна прогноза

Среден 18.67 USD  298.93%

Висок 25 USD

Нисък 15 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Abeona Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

3 ratings

3

Купи

0

Задържане

0

Продай

Финанси

$

Относно Abeona Therapeutics Inc

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.